Hepatitis C News

In a model presented at The Liver Meeting Digital Experience, experts showed that at-risk populations could be positively impacted by incremental changes in hepatitis C screening and treatment strategies.

In a comparison of two treatment models for HCV, researchers found that both were effective among people who injected drugs.

Using two methods of engagement – with methadone treatment or in a navigation setting – researchers at The Digital Liver Meeting Experience showed people who inject drugs can achieve viral response in hepatitis C virus.

Two epidemiological studies presented at The Digital Liver Meeting Experience revealed the work left in achieving elimination goals in hepatitis C virus.

Despite little contact with providers, patients in a minimal monitoring scenario achieved ‘cure’ of their hepatitis C virus, according to a presentation at The Digital Liver Meeting Experience.

In a minimal monitoring – or “Minmon” – study, patients given a full regimen for hepatitis C virus and then remotely monitored achieved 95% sustained virologic response, according to a presenter at The Liver Meeting Digital Experience.

Despite guidelines to ensure proper screening, one study presented during the Liver Meeting Digital Experience showed only 42% of infants born to women with hepatitis C and cirrhosis are screened and followed for hepatitis C.

The ACP has issued clinical advice for the treatment of hepatitis C virus infection in the Annals of Internal Medicine. The advice is based on WHO’s update to its evidence-based guidance in July 2018.

The Nobel Prize in Medicine was awarded to Harvey J. Alter, MD, Michael Houghton, PhD, DSc Hon and Charles M. RicePhD at the Karolinska Institutet in Sweden for the discovery of the hepatitis C virus.

Higher fibroscan liver stiffness after hepatitis C antiviral treatment was associated with the development of decompensated cirrhosis, according to study results.